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Abstract 
Purpose 
Chemotherapy for platinum resistant/refractory ovarian cancer is motivated by the 
hope of benefit. We sought to determine relationships between: a) trait hope, 
expectation of symptom benefit from chemotherapy, anxiety and depression; b) hope 
and perceived efficacy of chemotherapy; and c) dashed hope (where expectations 
for benefit are not fulfilled) and depression.   
Methods 
Adult patients enrolled within Stage 1 of the GCIG Symptom Benefit Study were 
included. Patient reported outcomes were collected at baseline, prior to the first 4 
treatment cycles (12 – 16 weeks) and 4 weeks after completing chemotherapy or at 
disease progression, whichever came first in 126 women with predominantly 
platinum resistant ovarian cancer. Associations were assessed with Spearman’s 
rank corrleation coefficient (r) and odds ratio. 
 
Results 
 
Trait hope and expectation of symptom benefit from chemotherapy were weakly 
correlated with each other (r 0.25). Trait hope, but not expectation of symptom 
benefit was negatively correlated with anxiety (r -0.43) and depression (r -0.50). The 
smaller the discrepancy between perceived and expected symptom benefit, the less 
likely the patient was to have scores indicative of depression (Odds ratio 0.68: 95% 
CI 0.49-0.96, P = 0.026).  
 
Conclusion 
Trait hope and expectation of symptom benefit from chemotherapy appear to be 
distinct, and independent of aspects quality of life and scores for depression. Hope 
did not appear to affect perceived efficacy of chemotherapy in alleviating symptoms, 
but women whose expectation of symptom benefit from chemotherapy was not 
fulfilled were more likely to have scores indicative of depression. It may be preferable 
to encourage hope towards achievable goals rather than benefits from 
chemotherapy.  
 
Abstract: 260  
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Introduction 
 
Ovarian cancer is the leading cause of death in women with gynecological 
malignancies in the Western World. Most women present with advanced disease 
and following surgery receive platinum based chemotherapy. Although many women 
initially respond to treatment, the majority will unfortunately relapse within 12-18 
months1. Patients who relapse within 6 months of receiving, or during, platinum-
based chemotherapy (platinum resistant /refractory) have a particularly poor 
prognosis, with a median survival ranging from 3-9 months 2-6.   Such women are 
usually offered 2nd or 3rd line chemotherapy with the aims of palliation and improving 
quality of life, with uncertain impact on overall survival.  
However, there are limited data on the actual impact of palliative chemotherapy on 
symptoms, or quality of life. In a prospective study of 27 women with recurrent 
ovarian cancer offered 2nd or 3rd line chemotherapy, only 7 had objective evidence of 
symptom improvement 7.   
Further, women’s expectations of therapy appear to be at odds with palliative aims. 
In the above study, despite having been told the goal of chemotherapy was 
palliative, 65% of women expected chemotherapy would make them live longer and 
42% thought it would cure them. This discrepancy has been reported in other 
advanced cancers 8. In another study of 122 women with ovarian cancer 8, 
approximately two thirds of women whose disease had relapsed ranked ‘tumour 
shrinkage’ as the ‘most important’ goal of treatment during repeated chemotherapy, 
with <8% rating symptom relief as the most important aim of treatment. Discordance 
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between doctors’ treatment intent and patients' beliefs about cure increased from 
24% at first-line to 83% by fourth-line chemotherapy. Many women, while 
acknowledging that their disease is incurable, seemingly choose to have 
chemotherapy as an antidote to hopelessness, to feel they are doing something, and 
have done everything possible to prolong life 9, 10. 
 
Some health professionals feel that maintenance of hope is a medically worthwhile 
outcome 9,10, providing meaning and direction 11-13 and improved coping and quality 
of life 12,14-17. However, it could also be argued that giving women “medically futile” 
treatment purely to maintain hope is questionable. If patients’ hopes are raised and 
then dashed, “false” hope may increase risk of depression, and side effects can 
further reduce wellbeing.  
 
Despite the common perception that hope is important, there is a lack of clarity in 
how the term is defined and measured 18. Some measures, such as the Herth Hope 
Index 19 portray hope as a general, multidimensional trait (trait hope). In contrast, 
others focus on a specific element of hope, such as hope for, or expectation of, a 
particular outcome (for example, symptom benefit from chemotherapy) 20,21. The 
degree to which hope is distinct from psychological morbidity (anxiety and 
depression) is not clear. Further research is needed to better understand the role of 
hope in maintaining wellbeing 22,23. In this study, we explored associations between 
hope, indices of wellbeing and perceived symptom benefits of chemotherapy.   
More specifically, we explored the following hypotheses in our population: 
1. Trait hope and the expectation of symptom benefit from chemotherapy are 
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separate concepts, and will be distinct from psychological well-being and quality 
of life. Thus at baseline, trait hope as measured by the Herth Hope Index will be 
moderately but not strongly correlated with expectation of symptom benefit, and 
each of these will correlate 
moderately but not strongly with anxiety, depression and quality of life. 
2. Trait hope and expectation of symptom benefit at baseline will be associated with 
perceived benefit from chemotherapy and improvement in self reported 
symptoms (FOSI) at follow-up after adjusting for anxiety and depression.  
3. Raised hope, if dashed, will leave patients vulnerable to depression. Thus 
disparity between expectation of symptom benefit and perceived symptom benefit 
from chemotherapy will be associated with increased depression (depression 
subscale of the HADS) at follow-up. 
4. Trait hope will modify the impact of a disparity between expectation of symptom 
benefit and perceived benefit on depression. 
Methods 
This sub-study was part of a larger study of symptom benefit in patients with 
platinum resistant/refractory ovarian cancer (Stage 1 of the GCIG Symptom Benefit 
Study (SBS)). This study sought to determine the aspects of HRQL rated most 
severe by patients, and the most common symptoms. All patients were recruited 
from centres in Australia and Canada, were ≥ 18 years, and had been diagnosed 
with epithelial ovarian, primary peritoneal or fallopian tube cancers. They all had 
recurrent cancer and progressive disease (based on CA125, radiological or clinical 
criteria). Patients with platinum resistant /refractory ovarian cancer were eligible (the 
vast majority of the sample), as were those with potentially platinum sensitive 
disease providing they were receiving their 3rd or greater line of treatment. All 
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patients were required to have an ECOG PS 0-3, a life expectancy of 3 months or 
longer, and be able to complete questionnaires independently. Choice of 
chemotherapy was at the discretion of the treating physician and had to commence 
within 2 weeks of registration.  No minimum threshold was set for symptom 
frequency or severity.   
Data was collected at baseline, prior to every treatment cycle for 4 treatment cycles 
(12 – 16 weeks) and one month post completion of treatment or at disease 
progression, whichever came first. 
 
Study Design  
The study had a longitudinal design with patient and clinician completed measures. 
The schedule for patient reported outcome measures is shown in Table 1. The 
questionnaires of relevance to this analysis included: 
 
1. The Herth Hope Index measures the degree to which a patient feels hope and a 
sense of meaning in their lives. The scale has three subscales: temporality and 
future, positive readiness and expectancy, and interconnectedness. High scores on 
the measure indicate greater hope. 19 
 
2. The Hospital Anxiety and Depression Scale (HADS) is comprised of 14 items in 
2 subscales independently measuring anxiety and depression24. Subscale scores of 
11 or more have been determined to be consistent with clinical anxiety or 
depression, with higher scores indicating higher anxiety and depression. 25 
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3. Expectation of symptom benefit and Perceived Benefit. At baseline and before 
starting chemotherapy patients were asked ‘How much do you expect your 
symptoms to improve with chemotherapy?’ using a numeric rating scale from 0 = 
“none at all” to 10 = “completely” (Expected benefit). At their follow up visits, after 
starting chemotherapy and prior to objective assessment of response, patients were 
asked: “How much have your symptoms improved with chemotherapy?” using the 
same scale (Perceived Benefit). If patients indicated an improvement in symptom 
control, they completed one item on a 5 point Likert scale (ranging from not at all to 
very much so) asking whether their symptom improvement was enough to affect 
their overall quality of life. 
 
4. Functional Assessment of Cancer Therapy – Ovary (FACT-O) Symptom 
Index (FOSI) 
is comprised of the FACT-G, a 28 item self reported measure that assesses four 
dimensions of well-being: physical, functional, social/family and emotional well-being, 
plus an ovarian cancer-specific subscale 26. The FOSI is a very brief (8-item) index 
derived from the FACT-O to measure symptom response to treatment for ovarian 
cancer (OC). High scores on FACT-O and FOSI indicate worse quality of life.  
 
(TABLE 1 ABOUT HERE) 
 
 
 
Statistical methods 
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Data were expressed as frequencies (percentages) for categorical variables and as 
means ± SD or medians (interquartile range) for normally and non-normally 
distributed continuous variables, respectively. The independent samples t-test was 
used to test for a difference in two group means. The FACT-O, FACT-G and FOSI 
scores were linearly transformed to a scale from 0 to 100.  
Spearman’s rank correlation coefficient (r) was used to examine the strength and 
direction of linear relationships between patient reported measurements (Hypothesis 
1). Consistent with Cohen, correlations from 0.10-0.29 were considered weak, from 
0.30-0.49 moderate and 0.50 or more strong 27. 
To assess improvement or deterioration in physical well-being, two methods were 
used: the change in FOSI score and the rating of perceived benefit.  An increase in 
FOSI score of at least 10 points (10% of total scale, approximately half a standard 
deviation) was classified as a significant improvement 28.  A rating of perceived 
benefit rating of 6 or more was classified as significant perceived improvement,  with 
this threshold representing scores of more than 10% above the median. Patients 
were then categorised as having improved physical well-being or not, and as having 
perceived benefit or not. Relationships between trait hope, expectation of  symptom 
benefit at baseline, and improvement in physical well being or perceived benefit at 
the end of treatment (Hypothesis 2) were assessed using logistic regression.  
Analyses with perceived benefit as the outcome were adjusted for anxiety and 
depression.  However adjustment was not possible in analyses predicting improved 
physical well being due to the small number of women experiencing improved 
physical well being 29.  
In the subgroup of patients without scores indicative of depression at baseline, the 
disparity between expectation of symptom benefit and perceived benefit was 
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determined by subtracting scores for perceived benefit from hope for symptom 
benefit.  Logistic regression was then performed to assess the relationship between 
that disparity and development of scores indicative of depression (Hypothesis 3).  
All statistical analyses were conducted using SAS software, version 9.2 (SAS 
Institute). Two-sided p-values <0.05 were considered statistically significant.. 
 
Results 
 
Characteristics and Symptom Complex at Baseline 
126 patients were recruited to the study and 123 had at least 1 cycle of 
chemotherapy. Their characteristics are shown in Table 2. Their mean age was 62 
years (range 30-89 years). The majority of patients had an ECOG performance 
status of 0 or 1 with 32% having a performance status of 0. Most patients had 
platinum resistant ovarian cancer and had received more than 2 lines of prior 
chemotherapy; 38% had received 3 or more lines of chemotherapy. 79% of patients 
reported at least one symptom at moderate or severe levels based on the Patient 
DATA Form30. 
 
(TABLE 2 ABOUT HERE) 
 
Hope, depression and anxiety and quality of life. 
Hope, depression, anxiety and quality of life scores at baseline and at the last follow-
up assessment are shown in Table 3.  
 
(TABLE 3 ABOUT HERE) 
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Expectation of symptom benefit and perceived benefit from chemotherapy 
Most patients expected that their symptoms would improve with treatment; 98% 
(N=121) expected some improvement (Expected Benefit score ≥1) 73% (N= 91) 
expected a significant improvement (Expected Benefit score ≥6), with 24% of 
patients (N=30) hoping that their symptoms would completely or almost completely 
resolve (Expected Benefit score 9 or 10). When asked at their last assessment how 
much their symptoms had improved, only 1 (1%) reported complete resolution of her 
symptoms, but at least 38% of patients reported that their symptoms had improved 
significantly (perceived benefit score of 6 or more). 
 
Correlations with hope at baseline 
There was a weak correlation between Trait hope and expectation of symptom 
benefit from chemotherapy (0.25), suggesting that they are related but distinct 
constructs (Table 4). Correlations between trait hope and measures of psychological 
well-being and quality of life were moderate: -0.43 with anxiety, 0.5 with depression, 
and 0.45 with emotional well-being on the FACT-O.  However there were no 
important correlations between expectation of symptom benefit and measures of 
psychological well being or quality of life (Table 4).  Thus our first hypothesis was 
partly supported.   
(TABLE 4 ABOUT HERE) 
 
Impact of baseline hope and expectation of symptom benefit, on perceived 
benefit and reported improvement in symptoms at follow-up 
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Contrary to Hypothesis 2, trait hope was not significantly associated with reported 
improvement in symptoms at follow-up based on either a 10 point increase in the 
FOSI symptom score, or on a perceived benefit rating greater than 5 (Table 5). Of 
those women who completed at least one on-treatment questionnaire, 44 (38%) 
reported a perceived benefit score >5 and 23 (20%) reported a FOSI score that 
increased by at least 10 points. Expectation of symptom benefit was also not 
associated with symptom improvement based on FOSI. 
In unadjusted analysis expectation of symptom benefit was associated with a higher 
likelihood of a perceived benefit rating greater than 5 (Odds Ratio: 1.25 95% CI 
(1.03-1.52); P = 0.022), however after adjustment for anxiety and depression the 
effect was attenuated and no longer siginficant (Table 5). 
Impact of disparity between expectation of symptom benefit and perceived 
benefit on development of depression 
Fourteen women had scores indicative of clinical depression at baseline.  Of the 111 
women without scores indicative of depression at baseline, 61 completed baseline 
and end of treatment (or last follow up) ratings of depression, expectation of 
symptom benefit, and perceived benefit. 39 of these 61 reported a perceived benefit 
less than their expected symptomatic benefit at baseline and were included in the 
following analysis to test Hypothesis 3. 
 
As hypothesised, the difference between expectation of symptom benefit and 
perceived benefit was significantly associated with follow-up scores indicative of 
depression; the greater the discrepancy between perceived benefit and expected 
symptom benefit, the greater the likelihood of a follow-up score indicative of 
depression (Odds ratio 0.68, 95% CI 0.49-0.96, P = 0.026). The mean difference 
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between expectation of symptom benefit and perceived benefit ratings among the 6 
patients with scores indicative of depression was -6.8 (95% CI -9.6 to -4.1) 
compared to -3.8 (95% CI -4.7 to -2.8) for the 33 patients who did not have scores 
indicative of depression (Difference in means test: P = 0.012). Thus hypothesis 3 
was supported, although should be interpreted cautiously given the small number of 
events. 
  
Role of trait hope in mitigating the impact of dashed expectations. 
 
Of the 39 evaluable patients who did not perceive a benefit from chemotherapy, 6 
had scores indicative of clinical depression at last follow up.  This number of events 
was insufficient to test for effect modification by levels of trait hope at baseline 
(Hypothesis 4).  
 
Discussion 
Our results support the distinction between general trait hope and specific 
expectation of symptom benefit from chemotherapy in women receiving palliative 
chemotherapy for platinum resistant/refractory ovarian cancer. Both hope constructs 
were independent of aspects of psychological well being and quality of life.  Contrary 
to our hypotheses, patients’ expectations at the beginning of treatment did not affect 
their perception of benefit from treatment.  Importantly, if there was a large 
discrepancy between expectations of symptom benefit and experienced benefit, 
women were more likely to have scores indicative of depression. This study lacked 
sufficient power to explore whether trait hope might mitigate the impact of such a 
discrepancy.  These results suggest that it might be helpful to assess women’s 
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expectations for benefit from chemotherapy in this setting.  Clinicians need to 
balance hope giving with a realistic appraisal of likely outcomes. 
 
Strategies for identifying and addressing unrealistic expectations in patients with 
advanced cancer have been proposed.  The inclusion of one negative or pessimistic 
statement in discussions about the future may limit overly optimistic expectations31, 
while use of decision aids describing average treatment outcomes 32, or  various 
scenarios (best, worst or typical cases) for prognosis33 have been demonstrated to 
be acceptable to patients34.  The provision of honest information did not dampen 
hope in one study32, suggesting honest and realistic information sensitively 
presented may be most effective at increasing understanding of realistic prognosis 
and potential benefits from treatment while maintaining hope. 
The maintenance of hope is considered by many to be an important goal of palliative  
chemotherapy for recurrent cancer35,36.  Hopefulness may be protective of overall 
psychological well being even in the face of a terminal diagnosis: we found that trait 
hope was moderately correlated with psychological well being and inversely 
correlated with anxiety and depression before starting palliative chemotherapy.   
 
Improvement in symptoms and overall quality of life is an important goal of treatment 
in recurrent ovarian cancer, and a large proportion of women in our study reported 
that they hoped to benefit substantially from chemotherapy (N =91, 73%).  The 
dilemma for many clinicians is how to provide a balance between realistic and 
truthful information regarding the likelihood of symptom benefit from palliative 
chemotherapy while, at the same time, maintaining appropriate levels of hope 21.  
The concern that false or unrealistic hope may ultimately prove to be 
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disadvantageous for the patient is not unwarranted.  Expectations that are 
unrealistically positive, for example maintaining a belief of cure in the terminal stages 
of an illness, can result in a lack of preparation for death that can lead to increased 
distress for patients and carers and exposure to avoidable futile interventions 37-40.  
In our study, patients with the greatest disparity between the improvement in 
symptoms they expected versus achieved, were most likely to have scores indicative 
of depression.  While acknowledging that hope for and expectation of benefit are 
closely related although not identical evaluations, this suggests that encouraging 
unrealistic hopes for symptom benefit may be harmful. 
It is unclear whether trait hope modifies the risk of developing depression when 
unrealistic expectations of symptom benefit are dashed.  The current study was 
underpowered to answer this question.  If this were so, it might indicate a potential 
protector against the disappointment of unrealised expectations, but one that is less 
amenable to intervention. 
 
The nature of hope for, or expectation of, treatment benefit may change with different 
goals along the course of the treatment trajectory. 41 It may therefore be appropriate 
to encourage patients to direct hope and expectation towards attainable goals that 
are meaningful for the individual patient 42-44. Appropriate levels of hope are hard to 
define and characterise, although misguided hope is often easier to recognise 45. 
The challenge for clinicians remains how to help individuals frame a difficult situation 
in an appropriately hopeful and helpful light.  This study suggests that a smaller 
disparity between expectations of benefit from chemotherapy may be associated 
with a lower risk of developing scores indicative of clinical levels of depression.  
Clinicians may be able to help lessen the disparity by encouraging hope for realistic 
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and achievable goals.    
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